p95HER2 and Breast Cancer
- 1 March 2011
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (5), 1515-1519
- https://doi.org/10.1158/0008-5472.can-10-3795
Abstract
A subtype of HER2-positive tumors with distinct biological and clinical features expresses a series of carboxy-terminal fragments collectively known as p95HER2. One of these fragments, named 100- to 115-kDa p95HER2 or 611-CTF, is hyperactive because of its ability to form homodimers maintained by intermolecular disulfide bonds. Despite lacking the majority of the extracellular domain, this HER2 fragment drives breast cancer progression in vivo. The recent availability of specific anti-p95 antibodies has confirmed previous results indicating that the expression of p95HER2 is predictive of poor prognosis and correlates with resistance to the treatment with trastuzumab, a therapeutic antibody directed against the extracellular domain of HER2. Cancer Res; 71(5); 1515–9. ©2011 AACR.Keywords
This publication has 26 references indexed in Scilit:
- A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast CancersCancer Research, 2010
- HER2 Carboxyl-terminal Fragments Regulate Cell Migration and Cortactin PhosphorylationOnline Journal of Public Health Informatics, 2009
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and MetastasisMolecular and Cellular Biology, 2009
- Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast CancerJNCI Journal of the National Cancer Institute, 2007
- Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translationThe EMBO Journal, 2006
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001